Polymedco will continue to distribute the complete line of FDI tumor markers, as well as the Polymedco bladder tumor antigen
To meet these criteria, substantial research has focused on developing a variety of potential biomarkers, including nuclear matrix protein, fibrin/fibrinogen product, bladder tumor antigen
, telomeric repeat amplification protocols (TRAP), tumor-associated antigens, hyaluronic acid, and hyaluronidase.
Recent reports have described the application of urine-based markers, including bladder tumor antigen
(BTA),6 nuclear matrix protein-22 (NMP22), and the urinary bladder cancer (UBC) test (5, 6).
In addition, a study by the Institute of Urology in Milan, published in the February 1999 issue of European Urology, concluded that the high sensitivity of NMP22 may provide significant improvement in the diagnosis of bladder cancer compared to urinary cytology or the bladder tumor antigen
Among these, Food and Drug Administration (FDA) approval for monitoring of patients with bladder cancer has been given to nuclear matrix protein (NMP) 22, fibrin /fibrinogen degradation product (FDP), and bladder tumor antigen
(BTA; Table 1).